ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00 AM ET in New York, New York.

A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, The webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit

Aclaris Therapeutics Contact:



EN
10/09/2024

Underlying

ACRSAclaris Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aclaris Therapeutics Inc.

 PRESS RELEASE
Free
ACRS Aclaris Therape...

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and ...

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update – First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced;Top-line Data Anticipated in First Half of 2025 – WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2024 and provided a corporate update. "The third quarter of 2024 marked an imp...

9h / 31m 1 EN
 PRESS RELEASE
Free
ACRS Aclaris Therape...

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinica...

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis WAYNE, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the first patient has been dosed in Aclaris' Phase 2a clinical trial of ATI-2138, an investigational oral covalent inhibitor of interleukin-2-inducible T cell kin...

September 17, 2024 1 EN
 PRESS RELEASE
Free
ACRS Aclaris Therape...

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthca...

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00 AM ET in New York, New York. A webcast of the fireside chat may be accessed through the “Events” page of the “In...

September 10, 2024 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
GEO GEO GROUP INC. ...
TPVG TRIPLEPOINT VEN... ... (+26)

InsiderInsights.com Daily Ratings Report: August 13, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

GEO GEO GROUP INC. (THE)
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
PAYC PAYCOM SOFTWARE INC.
FLDM FLUIDIGM
ACRS ACLARIS THERAPEUTICS INC.
CLOV CLOVER PAKISTAN LTD.
MYRG MYR GROUP INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
HMNF HMN FINANCIAL INC.
ELAN ELANCO ANIMAL HEALTH INC.
LYFT LYFT
PBYI INC.
PGEN INNOVATIVE ACQUISITIONS CORP
ALTG PRECIGEN INC
BIGC ALTA EQUIPMENT GROUP INC.
VMEO BIGCOMMERCE HOLDINGS
QSI INC.
GRNT VIMEO INC
MBC_w QUANTUM-SI INC
ET GRANITE RIDGE RESOURCES INC
GT MASTERBRAND INC
MIO ENERGY TRANSFER LP
FIP GOODYEAR TIRE & RUBBER CO.
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
FTAI INFRASTRUCTURE INC
08/14/24 August 14, 2024 1 EN
 PRESS RELEASE
Free
ACRS Aclaris Therape...

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and...

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update -Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million- WAYNE, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2024 and provided a corporate update. "Wi...

August 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch